近年來,在政府、研究學者與企業間的長期努力下,生技產業的規模蓬勃發展,體制愈趨完善。此外台灣「台灣生物經濟產業發展方案」也已於2016年元旦開始啟用,期望的是培養國內專業研發與銷售之人才,推廣產品到國際市場,增加台灣產業競爭力。但在生技產業中高獲利與聲譽佳的企業是否具有效率性?是否存在支出費用高但績效卻不好的情況?本研究利用資料包絡分析法(DEA),分析95家台灣生技公司進行之經營績效,各公司的投入資源,如固定資產、研究發展費用、推銷費用為投入項,營業收入為產出項,了解投入與產出之效率。此外透過BCG管理矩陣區分台灣生技績效較好之企業群,尋找可以讓同業仿效的標竿企業。 實證結果顯示:約有68.4%%的公司未達最適生產規模,針對這些公司,管理者應考慮減少投入項;約有31.6%績效佳的公司代表資源的分配與運用最具效率。另外,BCG中標竿組分別為精華、喬山、杏昌、百略、優盛、台欣生、泰博、美時、晟德、盛弘、東洋、健喬、中化、生達、旭富、台耀、葡萄王、中天、聯合、杏一、大江,這些公司在同業中成為被學習與模仿對象。
In recent years, with the efforts of Taiwan’s government and researcher, the scale of Biotech Industry in Taiwan has grown significantly. A Taiwan Bio-economic program has been started in 1 JAN 2016. It hopes to train research and development talents and sales personnel, and also to sell the products overseas. Do the Companies have the efficiency with a good reputation as well as high profit? Do the companies exist high expenses with bad performance? This research wants to use Data Envelopment Analysis (DEA) to analyze 95 Biotechnology Companies business performance in Taiwan. This research takes “fixed asset”, “R&D”, “sales expense” as input factor and “net income” as output factor. We use BCG Matrix to distinguish benchmark companies that can be imitated. The empirical results show that about 68.4% companies doesn’t achieve the optimum production scale in which managers should consider input reduction, and 31.6% good performance companies which represent the efficiency of distribution and resourcing. In addition, BCG Matrix’s results present that the market share and the efficient value of the benchmark companies are higher than the average industry group, which may become the subject of imitating and learning. Those companies are St. Shine, China Chemical, GKB, Standard Chemical, Johnson Health Tech., Hi-Clearance, Lotus Pharm., Microlife, TTY Biopharm, Synmosa, SCI Pharmtech, Rossmax, Center Lab., Microbio, United Orthopedic, Tyson, MedFirst, TaiDoc, FRMSL, ShareHope, TCI.